Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.

Advertisement

Related Content

Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
Neupogen Off-Label Use Complicates Data Extrapolation For Sandoz’s Biosimilar
What Will Biosimilar Labeling Look Like? Stakeholders Await FDA Guidance, Approvals
Biosimilar Guidance Puts BLA Sponsors On The Spot To Defend Reference Product Exclusivity
Sandoz’s Filgrastim Biosimilar Relies On Data Extrapolation
Waiting For Biosimilars: From Manufacturing To Litigation, Stakeholders Prepare For U.S. Market
Biosimilar Draft Guidance Outlines Three-Arm Bridging Studies For Non-U.S. Products
Lovenox Generics: FDA’s Split Opinion On ANDA Approval Fully Supported By Court
Biosimilar User Fee Agreement Allows For Reliance On Foreign Clinical Data, FDAer Says
FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel